Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 5,869 shares at $3.23 ($19K) on 2023-02-15, disclosed to the SEC on 2023-02-17.
Open-market sale of $19k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.16 | 196 | $619 | 3.3% |
| 2 | $3.19 | 5,665 | $18K | 96.6% |
| 3 | $3.23 | 8 | $26 | 0.1% |
| Total | $3.19 avg | 5,869 | $19K | 100% |
| Filing → |
| KPTI | SELL | 2026-03-03 | $48K | — | Filing → |
| KPTI | SELL | 2026-02-19 | $3K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |